Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-303 Treated RBCs in Acute Anemia
NCT01716923Phase 3Completed
- Sponsor
- Cerus Corporation
- Start
- Apr 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amustaline in anaemia (2 arms), sponsored by Cerus Corporation. Primary endpoints: Mean Hemoglobin Content at Day 2 and Adverse Events at 90 days. Started Apr 2013; status: completed.
02
Drugs
amustaline
03
Conditions
anaemia
Beyond the preview
Go deeper on NCT01716923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716923.